These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23807695)

  • 1. Adopting nested case-control quota sampling designs for the evaluation of risk markers.
    Zheng Y; Cai T; Pepe MS
    Lifetime Data Anal; 2013 Oct; 19(4):568-88. PubMed ID: 23807695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating prognostic accuracy of biomarkers in nested case-control studies.
    Cai T; Zheng Y
    Biostatistics; 2012 Jan; 13(1):89-100. PubMed ID: 21856652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk prediction measures for case-cohort and nested case-control designs: an application to cardiovascular disease.
    Ganna A; Reilly M; de Faire U; Pedersen N; Magnusson P; Ingelsson E
    Am J Epidemiol; 2012 Apr; 175(7):715-24. PubMed ID: 22396388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the predictive value of biomarkers with stratified case-cohort design.
    Liu D; Cai T; Zheng Y
    Biometrics; 2012 Dec; 68(4):1219-27. PubMed ID: 23173848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome-dependent sampling with interval-censored failure time data.
    Zhou Q; Cai J; Zhou H
    Biometrics; 2018 Mar; 74(1):58-67. PubMed ID: 28771664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating longitudinal markers under two-phase study designs.
    Maziarz M; Cai T; Qi L; Lok AS; Zheng Y
    Biostatistics; 2019 Jul; 20(3):485-498. PubMed ID: 29912281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cox regression in nested case-control studies with auxiliary covariates.
    Liu M; Lu W; Tseng CH
    Biometrics; 2010 Jun; 66(2):374-81. PubMed ID: 19508242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating incremental values from new predictors with net reclassification improvement in survival analysis.
    Zheng Y; Parast L; Cai T; Brown M
    Lifetime Data Anal; 2013 Jul; 19(3):350-70. PubMed ID: 23254468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. External comparisons from nested case-control designs.
    Suissa S; Edwardes MD; Boivin JF
    Epidemiology; 1998 Jan; 9(1):72-8. PubMed ID: 9430272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Robust risk prediction with biomarkers under two-phase stratified cohort design.
    Payne R; Yang M; Zheng Y; Jensen MK; Cai T
    Biometrics; 2016 Dec; 72(4):1037-1045. PubMed ID: 27037494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IMPROVING EFFICIENCY IN BIOMARKER INCREMENTAL VALUE EVALUATION UNDER TWO-PHASE DESIGNS.
    Zheng Y; Brown M; Lok A; Cai T
    Ann Appl Stat; 2017 Jun; 11(2):638-654. PubMed ID: 28943991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semiparametric isotonic regression analysis for risk assessment under nested case-control and case-cohort designs.
    Li W; Li R; Feng Z; Ning J
    Stat Methods Med Res; 2020 Aug; 29(8):2328-2343. PubMed ID: 31868119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of case-cohort designs with binary outcomes: Improving efficiency using whole-cohort auxiliary information.
    Noma H; Tanaka S
    Stat Methods Med Res; 2017 Apr; 26(2):691-706. PubMed ID: 25348675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which patients to sample in clinical cohort studies when the number of events is high and measurement of additional markers is constrained by limited resources.
    Edelmann D; Ohneberg K; Becker N; Benner A; Schumacher M
    Cancer Med; 2020 Oct; 9(20):7398-7406. PubMed ID: 32813923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study.
    Wang TJ; Wollert KC; Larson MG; Coglianese E; McCabe EL; Cheng S; Ho JE; Fradley MG; Ghorbani A; Xanthakis V; Kempf T; Benjamin EJ; Levy D; Vasan RS; Januzzi JL
    Circulation; 2012 Sep; 126(13):1596-604. PubMed ID: 22907935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation based on case-control designs with known prevalence probability.
    van der Laan MJ
    Int J Biostat; 2008; 4(1):Article 17. PubMed ID: 22462152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Group sequential testing of the predictive accuracy of a continuous biomarker with unknown prevalence.
    Koopmeiners JS; Feng Z
    Stat Med; 2016 Apr; 35(8):1267-80. PubMed ID: 26537180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semiparametric inference for a two-stage outcome-dependent sampling design with interval-censored failure time data.
    Zhou Q; Cai J; Zhou H
    Lifetime Data Anal; 2020 Jan; 26(1):85-108. PubMed ID: 30617753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sampling strategies to evaluate the prognostic value of a new biomarker on a time-to-event end-point.
    Graziano F; Valsecchi MG; Rebora P
    BMC Med Res Methodol; 2021 Apr; 21(1):93. PubMed ID: 33941092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-sensitivity C-reactive protein can predict major adverse cardiovascular events in Korean patients with type 2 diabetes.
    Lee S; Kim IT; Park HB; Hyun YK; Kim YJ; Song SO; Kim H
    J Korean Med Sci; 2011 Oct; 26(10):1322-7. PubMed ID: 22022185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.